Skip to main content

Advertisement

SpringerLink
Log in

Remodeling and skeletal fragility

  • Review
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Parfitt AM (2002) High bone turnover is intrinsically harmful: two paths to a similar conclusion. The Parfitt view. J Bone Miner Res 17:1558–1559; discussion 1560

    PubMed  Google Scholar 

  2. Cummings SR, Karpf DB, Harris F, et al (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289

    Article  CAS  PubMed  Google Scholar 

  3. Sarkar S, Mitlak B, Wong M, et al (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10

    CAS  PubMed  Google Scholar 

  4. Bjarnason NH, Sarkar S, Duong T, et al (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922–930

    Article  CAS  PubMed  Google Scholar 

  5. Heaney RP (1994) The bone remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 9:1515–1523

    CAS  PubMed  Google Scholar 

  6. Heaney RP, Yates AJ, Santora AC (1997) Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 12:1143–1151

    CAS  PubMed  Google Scholar 

  7. Khosla S, Melton III LJ, Wermers R, et al (1999) Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14:1700–1707

    CAS  PubMed  Google Scholar 

  8. Bilezekian J (2003). Bone strength in primary hyperparathyroidism. Osteoporos Int (in press)

  9. Garnero P, Hausherr E, Chapuy MC, et al (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531–1538

    CAS  PubMed  Google Scholar 

  10. Recker R (2003) Effects of dose selection of 3-monthly intravenous ibandronate injections for the development of a new treatment paradigm. Arch Intern Med (in press)

  11. Langdahl B, Mortensen L, Vesterby A, Eriksen E, Charles P (1996) Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone 18:103–108

    Article  CAS  PubMed  Google Scholar 

  12. Mashiba T, Turner CH, Hirano T, et al (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531

    Article  CAS  PubMed  Google Scholar 

  13. Li J, Mashiba T, Burr DB (2001) Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69:281–286

    CAS  PubMed  Google Scholar 

  14. Heaney R, Whedon G (1958) Radiocalcium studies of bone formation rate in human metabolic bone disease. J Clin Endocrinol Metab 18:1246–1267

    Google Scholar 

  15. Wastney ME, Martin BR, Peacock M, et al (2000) Changes in calcium kinetics in adolescent girls induced by high calcium intake. J Clin Endocrinol Metab 85:4470–4475

    Google Scholar 

  16. Heaney RP, Dowell M, Bierman J, Hale C, Bendich A (2001) Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr 20:239–246

    CAS  PubMed  Google Scholar 

  17. Heaney R, Recker R, Saville P (1978) Menopausal changes in bone remodeling. J Lab Clin Med 92:964–970

    CAS  PubMed  Google Scholar 

  18. Heaney R, Recker R, Saville P (1977) Calcium balance and calcium requirements in middle-aged women. Am J Clin Nutr 30:1603–1611

    CAS  PubMed  Google Scholar 

  19. Abbott S, Trinkaus E, Burr D (1996) Dynamic bone remodeling in later Pleistocene fossil hominids. Am J Phys Anthropol 99:585–601

    Article  CAS  PubMed  Google Scholar 

  20. Paschallis E, Phipps R (2002) Three-years treatment with risedronate does not alter bone mineral crystallinity in post-menopausal osteoporotic subjects. J Bone Miner Res 17 [Suppl 1]:S368

Download references

Author information

Consortia

Robert P. Heaney

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robert P. Heaney. Remodeling and skeletal fragility. Osteoporos Int 14 (Suppl 5), 12–15 (2003). https://doi.org/10.1007/s00198-003-1466-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-003-1466-4

Keywords

Search

Navigation